Factors Associated with Pain Treatment Satisfaction Among Patients with Chronic Non-Cancer Pain and Substance Use

References

1. 1.↵
   Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington: National Academies Press; 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK91497/.
2. 2.↵
   1. Dahlhamer J,
   2. Lucas J,
   3. Zelaya C,
   4. et al

   . Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:1001–6.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Bouhassira D,
   2. Lantéri-Minet M,
   3. Attal N,
   4. Laurent B,
   5. Touboul C

   . Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380–7.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Liebschutz JM,
   2. Saitz R,
   3. Weiss RD,
   4. et al

   . Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 2010;11:1047–55.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Hurstak EE,
   2. Kushel M,
   3. Chang J,
   4. et al

   . The risks of opioid treatment: perspectives of primary care practitioners and patients from safety-net clinics. Subst Abuse 2017;38:213–21.

   OpenUrl
6. 6.↵
   1. Chao MT,
   2. Hurstak E,
   3. Leonoudakis-Watts K,
   4. et al

   . Patient-reported outcomes of an integrative pain management program implemented in a primary care safety net clinic: a quasi-experimental study. J Gen Intern Med 2019;34:1105–7.

   OpenUrl
7. 7.↵
   1. Hurstak E,
   2. Chao MT,
   3. Leonoudakis-Watts K,
   4. Pace J,
   5. Walcer B,
   6. Wismer B

   . Design, implementation, and evaluation of an integrative pain management program in a primary care safety-net clinic. J Altern Complement Med 2019;25:S78–S85.

   OpenUrl
8. 8.↵
   1. Knight KR,
   2. Kushel M,
   3. Chang JS,
   4. et al

   . Opioid pharmacovigilance: a clinical-social history of the changes in opioid prescribing for patients with co-occurring chronic non-cancer pain and substance use. Soc Sci Med 2017;186:87–95.

   OpenUrl
9. 9.↵
   1. Hirsh AT,
   2. Atchison JW,
   3. Berger JJ,
   4. et al

   . Patient satisfaction with treatment for chronic pain: predictors and relationship to compliance. Clin J Pain 2005;21:302–10.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Prakash B

    . Patient satisfaction. J Cutan Aesthet Surg 2010;3:151–5.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Gruß I,
    2. Firemark A,
    3. McMullen CK,
    4. Mayhew M,
    5. DeBar LL

    . Satisfaction with primary care providers and health care services among patients with chronic pain: a mixed-methods study. J Gen Intern Med 2020;35:190–7.

    OpenUrl
12. 12.↵
    1. Sherwood G,
    2. Adams-McNeill J,
    3. Starck PL,
    4. Nieto B,
    5. Thompson CJ

    . Qualitative assessment of hospitalized patients' satisfaction with pain management. Res Nurs Health 2000;23:486–95.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Isenberg SR,
    2. Maragh-Bass AC,
    3. Ridgeway K,
    4. Beach MC,
    5. Knowlton AR

    . A qualitative exploration of chronic pain and opioid treatment among HIV patients with drug use disorders. J Opioid Manag 2017;13:5–16.

    OpenUrl
14. 14.↵
    1. Dassieu L,
    2. Kaboré J-L,
    3. Choinière M,
    4. Arruda N,
    5. Roy É

    . Chronic pain management among people who use drugs: a health policy challenge in the context of the opioid crisis. Int J Drug Policy 2019;71:150–6.

    OpenUrlPubMed
15. 15.↵
    1. Edlund MJ,
    2. Martin BC,
    3. Devries A,
    4. Fan M-Y,
    5. Braden JB,
    6. Sullivan MD

    . Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain 2010;26:1–8.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Vijayaraghavan M,
    2. Penko J,
    3. Guzman D,
    4. Miaskowski C,
    5. Kushel MB

    . Primary care providers' views on chronic pain management among high-risk patients in safety net settings. Pain Med 2012;13:1141–8.

    OpenUrl
17. 17.↵
    1. Guy GP,
    2. Zhang K,
    3. Bohm MK,
    4. et al

    . Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697–704.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Bohnert ASB,
    2. Guy GP,
    3. Losby JL

    . Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention's 2016 opioid guideline. Ann Intern Med 2018;169:367–75.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Chang JS,
    2. Kushel M,
    3. Miaskowski C,
    4. et al

    . Provider experiences with the identification, management, and treatment of co-occurring chronic non-cancer pain and substance use in the safety net. Subst Use Misuse 2017;52:251–5.

    OpenUrl
20. 20.↵
    1. Busch SH,
    2. Meara E,
    3. Huskamp HA,
    4. Barry CL

    . Characteristics of adults with substance use disorders expected to be eligible for Medicaid under the ACA. PS 2013;64:520–6.

    OpenUrl
21. 21.↵
    1. Laverdiere D,
    2. Pereyda M,
    3. Silva J,
    4. Tatar M

    . Changing course: the role of health plans in curbing the opioid epidemic. Oakland: California Health Care Foundation; 2016. p. 35. Available from: https://www.chcf.org/wp-content/uploads/2017/12/PDF-ChangingHealthPlansOpioid.pdf.
22. 22.↵
    American Medical Association. National roadmap on state-level efforts to end the opioid epidemic. Chicago: AMA; 2019. p. 27. Available from: https://www.ama-assn.org/delivering-care/opioids/reversing-opioid-epidemic.
23. 23.↵
    1. Coffin PO,
    2. Rowe C,
    3. Gerbino N

    . Substance use trends in San Francisco through 2019. Gainesville, FL: National Drug Early Warning System (NDEWS) Coordinating Center; 2020. Available from: https://www.csuhsf.org/substance-use-trends-san-francisco.
24. 24.↵
    1. Dowell D,
    2. Haegerich TM,
    3. Chou R

    . CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. JAMA 2016;315:1624–45.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Denis CM,
    2. Morales KH,
    3. Wu Q,
    4. Metzger DS,
    5. Cheatle MD

    . Association between diagnoses of chronic noncancer pain, substance use disorder, and HIV-related outcomes in people living with HIV. J Acquir Immune Defic Syndr 2019;82 Suppl 2:S142–S147.

    OpenUrl
26. 26.↵
    1. Piper BJ,
    2. Beals ML,
    3. Abess AT,
    4. et al

    . Chronic pain patients' perspectives of medical cannabis. Pain 2017;158:1373–9.

    OpenUrlPubMed
27. 27.↵
    1. Tate CC,
    2. Ledbetter JN,
    3. Youssef CP

    . A two-question method for assessing gender categories in the social and medical sciences. J Sex Res 2013;50:767–76.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Prins A,
    2. Ouimette P,
    3. Kimerling R,
    4. et al

    . The Primary Care PTSD Screen (PC-PTSD): development and operating characteristics. Prim Care Psych 2004;9:9–14.

    OpenUrl
29. 29.↵
    1. Kroenke K,
    2. Strine TW,
    3. Spitzer RL,
    4. Williams JBW,
    5. Berry JT,
    6. Mokdad AH

    . The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009;114:163–73.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Dhingra SS,
    2. Kroenke K,
    3. Zack MM,
    4. Strine TW,
    5. Balluz LS

    . PHQ-8 days: a measurement option for DSM-5 Major Depressive Disorder (MDD) severity. Popul Health Metr 2011;9:11.

    OpenUrlPubMed
31. 31.↵
    1. Recklitis CJ,
    2. Blackmon JE,
    3. Chang G

    . Validity of the Brief Symptom Inventory-18 (BSI-18) for identifying depression and anxiety in young adult cancer survivors: comparison with a structured clinical diagnostic interview. Psychol Assess 2017;29:1189–200.

    OpenUrlCrossRef
32. 32.↵
    1. Kerper LF,
    2. Spies CD,
    3. Tillinger J,
    4. et al

    . Screening for depression, anxiety, and general psychological distress in pre-operative surgical patients: a psychometric analysis of the Patient Health Questionnaire 4 (PHQ-4). clinhp 2014;5–14.
33. 33.↵
    1. Derogatis LR

    . Brief Symptom Inventory (BSI)-18: administration, scoring and procedures manual; 2001. Available from: http://www.pearsonclinical.com/psychology/products/100000638/brief-symptom-inventory-18-bsi-18.html.
34. 34.↵
    1. Leung L

    . Pain catastrophizing: an updated review. Indian J Psychol Med 2012;34:204–17.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. Osman A,
    2. Barrios FX,
    3. Gutierrez PM,
    4. Kopper BA,
    5. Merrifield T,
    6. Grittmann L

    . The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. J Behav Med 2000;23:351–65.

    OpenUrlCrossRefPubMedWeb of Science
36. 36.↵
    1. Kortlever JTP,
    2. Janssen SJ,
    3. van Berckel MMG,
    4. Ring D,
    5. Vranceanu AM

    . What is the most useful questionnaire for measurement of coping strategies in response to nociception? Clin Orthop Relat Res 2015;473:3511–8.

    OpenUrl
37. 37.↵
    1. Hansen L,
    2. Penko J,
    3. Guzman D,
    4. Bangsberg DR,
    5. Miaskowski C,
    6. Kushel MB

    . Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals. J Pain Symptom Manage 2011;42:893–902.

    OpenUrlPubMed
38. 38.↵
    1. Penko J,
    2. Mattson J,
    3. Miaskowski C,
    4. Kushel M

    . Do patients know they are on pain medication agreements? Results from a sample of high-risk patients on chronic opioid therapy. Pain Med 2012;13:1174–80.

    OpenUrl
39. 39.↵
    1. McIntyre MH,
    2. Kless A,
    3. Hein P,
    4. Field M,
    5. Tung JY

    , Team 23andMe Research. Validity of the cold pressor test and pain sensitivity questionnaire via online self-administration. PLoS One 2020;15:e0231697.

    OpenUrlCrossRef
40. 40.↵
    1. Modir JG,
    2. Wallace MS

    . Human experimental pain models 2: the cold pressor model. Methods Mol Biol 2010;617:165–8.

    OpenUrlPubMed
41. 41.↵
    1. Wilkins CH,
    2. Roe CM,
    3. Morris JC

    . A brief clinical tool to assess physical function: the mini-physical performance test. Arch Gerontol Geriatr 2010;50:96–100.

    OpenUrlPubMed
42. 42.↵
    1. Morasco BJ,
    2. Lovejoy TI,
    3. Turk DC,
    4. Crain A,
    5. Hauser P,
    6. Dobscha SK

    . Biopsychosocial factors associated with pain in veterans with the hepatitis C virus. J Behav Med 2014;37:902–11.

    OpenUrlCrossRefPubMed
43. 43.↵
    Centers for Disease Control and Prevention. Calculating total daily dose of opioids for safer dosage; 2019. Available from: https://www.cdc.gov/drugoverdose/pdf/prescribing/Guidelines_Factsheet-a.pdf.
44. 44.↵
    1. Nielsen S,
    2. Degenhardt L,
    3. Hoban B,
    4. Gisev N

    . A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf 2016;25:733–7.

    OpenUrlPubMed
45. 45.↵
    Centers for Disease Control and Prevention. Pocket guide: tapering opioids for chronic pain. Available from: https://www.cdc.gov/drugoverdose/pdf/clinical_pocket_guide_tapering-a.pdf.
46. 46.↵
    1. Kertesz SG

    . Outcomes after opioid dose reductions and stoppage: it's time to start counting. J Subst Abuse Treat 2019;103:64–5.

    OpenUrl
47. 47.↵
    1. Kertesz SG,
    2. Manhapra A,
    3. Gordon AJ

    . Nonconsensual dose reduction mandates are not justified clinically or ethically: an analysis. J Law Med Ethics 2020;48:259–67.

    OpenUrl
48. 48.↵
    1. Frank JW,
    2. Lovejoy TI,
    3. Becker WC,
    4. et al

    . Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy. Ann Intern Med 2017;167:181–91.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. McPherson S,
    2. Smith CL,
    3. Dobscha SK,
    4. et al

    . Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain. Pain 2018;159:2097–104.

    OpenUrl
50. 50.↵
    1. Coffin PO,
    2. Rowe C,
    3. Oman N,
    4. et al

    . Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain. PLoS ONE 2020;15:e0232538.

    OpenUrl
51. 51.↵
    1. James JR,
    2. Scott JM,
    3. Klein JW,
    4. et al

    . Mortality after discontinuation of primary care-based chronic opioid therapy for pain: a retrospective cohort study. J Gen Intern Med 2019;34:2749–55.

    OpenUrlCrossRefPubMed
52. 52.↵
    1. Demidenko MI,
    2. Dobscha SK,
    3. Morasco BJ,
    4. Meath THA,
    5. Ilgen MA,
    6. Lovejoy TI

    . Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users. Gen Hosp Psychiatry 2017;47:29–35.

    OpenUrlCrossRefPubMed
53. 53.↵
    1. Oliva EM,
    2. Bowe T,
    3. Manhapra A,
    4. et al

    . Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ 2020;m283.
54. 54.↵
    1. Mark TL,
    2. Parish W

    . Opioid medication discontinuation and risk of adverse opioid-related health care events. Subst Abuse 2019;103:58–63.

    OpenUrl
55. 55.↵
    1. Fischer B,
    2. Jones W,
    3. Tyndall M,
    4. Kurdyak P

    . Correlations between opioid mortality increases related to illicit/synthetic opioids and reductions of medical opioid dispensing—exploratory analyses from Canada. BMC Public Health 2020;20:143.

    OpenUrl
56. 56.↵
    1. Behar E,
    2. Bagnulo R,
    3. Knight K,
    4. Santos G-M,
    5. Coffin PO

    . “Chasing the pain relief, not the high”: experiences managing pain after opioid reductions among patients with HIV and a history of substance use. PLoS One 2020;15:e0230408.

    OpenUrl
57. 57.↵
    1. Kroenke K,
    2. Alford DP,
    3. Argoff C,
    4. et al

    . Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: a consensus panel report. Pain Med 2019;20:724–35.

    OpenUrl
58. 58.↵
    1. Glowacki D

    . Effective pain management and improvements in patients' outcomes and satisfaction. Crit Care Nurse 2015;35:33–41.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    1. Hassan AN,
    2. Le Foll B,
    3. Imtiaz S,
    4. Rehm J

    . The effect of post-traumatic stress disorder on the risk of developing prescription opioid use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. Drug Alcohol Depend 2017;179:260–6.

    OpenUrl
60. 60.↵
    1. Park TW,
    2. Lin LA,
    3. Hosanagar A,
    4. Kogowski A,
    5. Paige K,
    6. Bohnert ASB

    . Understanding risk factors for opioid overdose in clinical populations to inform treatment and policy. J Addict Med 2016;10:369–81.

    OpenUrl
61. 61.↵
    1. Cody GR,
    2. Wang B,
    3. Link AR,
    4. Sherman SE

    . Characteristics of urban inpatient smokers with and without chronic pain: foundations for targeted cessation programs. Subst Use Misuse 2019;54:1138–45.

    OpenUrl
62. 62.↵
    1. Zvolensky MJ,
    2. McMillan K,
    3. Gonzalez A,
    4. Asmundson GJG

    . Chronic pain and cigarette smoking and nicotine dependence among a representative sample of adults. Nicotine Tob Res 2009;11:1407–14.

    OpenUrlCrossRefPubMedWeb of Science
63. 63.↵
    1. Goesling J,
    2. Brummett CM,
    3. Meraj TS,
    4. Moser SE,
    5. Hassett AL,
    6. Ditre JW

    . Associations between pain, current tobacco smoking, depression, and fibromyalgia status among treatment-seeking chronic pain patients. Pain Med 2015;16:1433–42.

    OpenUrl
64. 64.↵
    1. Bonnie RJ,
    2. Stratton K,
    3. Kwan LY

    . The effects of tobacco use on health; 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK310413/.
65. 65.↵
    1. Cunningham CO

    . Opioids and HIV infection: from pain management to addiction treatment. Top Antivir Med 2018;25:143–6.

    OpenUrl
66. 66.↵
    1. Edelman EJ,
    2. Gordon K,
    3. Becker WC,
    4. et al

    . Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med 2013;28:82–90.

    OpenUrlCrossRefPubMed
67. 67.↵
    1. Horberg MA,
    2. Hurley LB,
    3. Towner WJ,
    4. et al

    . Determination of optimized multidisciplinary care team for maximal antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2012;60:183–90.

    OpenUrlCrossRefPubMed
68. 68.↵
    1. Zaller N,
    2. Gillani FS,
    3. Rich JD

    . A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care 2007;19:1128–33.

    OpenUrlPubMed
69. 69.↵
    1. Merlin JS,
    2. Long D,
    3. Becker WC,
    4. et al

    . Brief report: the association of chronic pain and long-term opioid therapy with HIV treatment outcomes. J Acquir Immune Defic Syndr 2018;79:77–82.

    OpenUrl
70. 70.↵
    1. Starrels JL,
    2. Peyser D,
    3. Haughton L,
    4. et al

    . When human immunodeficiency virus (HIV) treatment goals conflict with guideline-based opioid prescribing: a qualitative study of HIV treatment providers. Subst Abuse 2016;37:148–53.

    OpenUrl
71. 71.↵
    1. Cuca YP,
    2. Shumway M,
    3. Machtinger EL,
    4. et al

    . The association of trauma with the physical, behavioral, and social health of women living with HIV: pathways to guide trauma-informed health care interventions. Womens Health Issues 2019;29:376–84.

    OpenUrl
72. 72.↵
    1. Sohler NL,
    2. Starrels JL,
    3. Khalid L,
    4. et al

    . Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain. Subst Use Misuse 2018;53:1602–7.

    OpenUrl
73. 73.↵
    1. Merlin JS,
    2. Long D,
    3. Becker WC,
    4. et al

    . Marijuana use is not associated with changes in opioid prescriptions or pain severity among people living with HIV and chronic pain. J Acquir Immune Defic Syndr 2019;81:231–7.

    OpenUrl
74. 74.↵
    1. Merlin JS,
    2. Samet JH,
    3. Cheng DM,
    4. et al

    . Marijuana use and its associations with pain, opioid dose, and HIV viral suppression among persons living with HIV on chronic opioid therapy. J Acquir Immune Defic Syndr 2019;82:195–201.

    OpenUrl
75. 75.↵
    1. Romero-Sandoval EA,
    2. Kolano AL,
    3. Alvarado-Vázquez PA

    . Cannabis and cannabinoids for chronic pain. Curr Rheumatol Rep 2017;19:67.

    OpenUrl
76. 76.↵
    1. Ishida JH,
    2. Wong PO,
    3. Cohen BE,
    4. Vali M,
    5. Steigerwald S,
    6. Keyhani S

    . Substitution of marijuana for opioids in a national survey of US adults. PLoS ONE 2019;14:e0222577.

    OpenUrlPubMed
77. 77.↵
    1. Campbell G,
    2. Hall WD,
    3. Peacock A,
    4. et al

    . Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health 2018;3:e341–e350.

    OpenUrl
78. 78.↵
    1. Cooke AC,
    2. Knight KR,
    3. Miaskowski C

    . Patients' and clinicians' perspectives of co-use of cannabis and opioids for chronic non-cancer pain management in primary care. Int J Drug Policy 2019;63:23–8.

    OpenUrlPubMed
79. 79.↵
    1. Deshpande A,
    2. Mailis-Gagnon A,
    3. Zoheiry N,
    4. Lakha SF

    . Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Physician 2015;61:e372–e381.

    OpenUrlAbstract/FREE Full Text